KEY TAKEAWAYS GSK shares in London jumped 5% Thursday after the British pharmaceutical giant said it has resolved most of the U.S. lawsuits it faced around claims that its discontinued heartburn medicine Zantac causes cancer. The London-listed firm said it had struck agreements to resolve 93%, or about 80,000, of the pending Zantac lawsuits in the U.S. and will make a total payment of up to $2.2 billion to settle them. GSK said the plaintiffs are unanimously recommending their clients accept the settlement. ...

In a swarm of lawsuits, the company stood accused of selling a potentially cancer-causing medication. Thanks largely to news of a crucial legal settlement, GSK (GSK 5.84%) was one of the better-performing big pharma stocks on Wednesday. Relieved investors showed their appreciation by collectively bidding the company's shares up by 5.8% on the day, a performance that easily eclipsed the 0.7% rise of the benchmark S&P 500 index. $2.2 billion-plus in settlements That news concerns a discontinued version of GSK ...

GlaxoSmithKline (GSK, Financial) has agreed to a substantial settlement in connection with lawsuits related to its Zantac product in U.S. state courts. The company announced that it reached settlements with 10 plaintiff firms, which represent a significant 93% of the cases filed against the pharmaceutical company regarding Zantac. The total settlement amount is up to $2.2 billion. ...

GSK (GSK, Financial) announced that its respiratory syncytial virus (RSV) vaccine has shown protective benefits for three quarters following vaccination. The cumulative efficacy of the vaccine, adjusted for seasonal factors, stands at 62.9% for the elderly. This data is crucial for advisory panels, doctors, and patients when deciding which RSV vaccine to choose, as GSK faces strong competition from Pfizer (PFE) and Moderna (MRNA). The vaccine is approved for all adults aged 60 and above in the US and EU, as ...

Industry Overview - Recent data indicates a significant drop in the sales of the respiratory syncytial virus (RSV) vaccine in the United States, with independent pharmacists reporting a two-thirds decline in RSV vaccine uptake compared to the previous year [1][3] - RSV poses a severe health risk to infants, older adults, and individuals with compromised immune systems, leading to numerous hospitalizations and deaths annually [2] Company Performance - GSK's sales for Arexvy, the first RSV vaccine approved in May of last year, might fall short of Wall Street's expectations for Q3, with a spokesperson remaining optimistic about the vaccine's growth potential [4] - In 2023, GSK achieved $1.564 billion in RSV vaccine sales, while Pfizer recorded $890 million, half of GSK's figures [5] - Market predictions suggest a slight decrease in GSK's sales to approximately $1.5 billion this year, whereas Pfizer's sales are expected to rise nearly 40% to $1.2 billion [5] Regulatory Impact - The decline in RSV vaccine demand is attributed to a CDC decision in June that narrowed its recommendations for older adults, refraining from advising those under 60 to receive the vaccine [3]

GSK plc (GSK) announced positive topline results from a phase III study evaluating the co-administration of its two marketed vaccines — RSV vaccine Arexvy and shingles vaccine Shingrix — in older adults (aged 50 years and older). The study achieved its primary endpoint of non-inferior immune response — study participants who received the co-administered shot generated immune responses that were similar to those generated in participants who received each vaccine separately. Study participants who received t ...

Core Insights - Kalm Therapeutics has appointed Dr. Tomoko Maeda-Chubachi as Chief Medical Officer to oversee the design and submission of their Phase 1b/2a clinical trial protocol to the FDA [1][4] Company Overview - Kalm Therapeutics, founded in 2024, is a pre-clinical drug development company focused on a medicated, controlled-release patch for the non-steroidal treatment of mild to moderate atopic dermatitis and psoriasis [4] Leadership Experience - Dr. Maeda-Chubachi has extensive experience in dermatology drug development, having worked with Pfizer, Eli Lilly, and GSK, where she led the Phase II clinical trial of the eczema/psoriasis topical cream Vtama, which was acquired by Dermavant for $250 million [3] - Most recently, she served as Chief Medical Officer at Pelthos Therapeutics, where she led the approval of Zelsuvmi for molluscum contagiosum [3] Industry Context - Eczema remains a complex disease requiring diverse therapeutic options, and Dr. Maeda-Chubachi expressed excitement about developing the Kalm Patch as a new management solution for eczema [2]

GSK plc (GSK) announced that its therapeutic herpes simplex virus (HSV) vaccine candidate, GSK3943104, did not meet the primary endpoint in the combined phase I/II proof-of-concept study. The phase I/II TH HSV REC-003 study evaluated the clinical efficacy of the early-stage HSV vaccine candidate GSK3943104. The company completed the primary objective data analysis from the phase II part of the phase I/II TH HSV REC-003 study, which demonstrated that GSK3943104 failed to meet the study's primary efficacy end ...

GSK's (GSK) phase III study evaluating its blockbuster drug Nucala (mepolizumab), an anti-IL5 biologic, for treating chronic obstructive pulmonary disease (COPD), met its primary endpoint. Data from the MATINEE study showed that in patients treated for up to 2 years, the addition of Nucala to inhaled maintenance therapy led to a statistically significant and clinically meaningful reduction in the annualized rate of moderate/severe exacerbations versus placebo, thereby meeting the study's primary endpoint. C ...

GSK plc (GSK) has announced the approval of the European Commission (EC) for the expanded use of its respiratory syncytial virus (RSV) vaccine, Arexvy, in adults aged 50-59 years. The vaccine has been approved for the prevention of lower respiratory tract disease (LRTD) caused by RSV in patients aged 50-59 years who are at increased risk of the disease. In the European Union (EU), there are around 65 million adults aged 50-59 years who are at increased risk for RSV disease. Out of these, an estimated 20 mil ...